News
In brief
BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7344.994/b (Published 27 April 2002) Cite this as: BMJ 2002;324:994
This article has a correction. Please see:
FDA demands warning label on rofecoxib: The US Food and Drug Administration has ordered drug manufacturer Merck to put a warning label on the cyclo-oxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx) stating that it can raise blood pressure and may increase the risk of heart attacks; the move follows research findings on the drug's side effects (BMJ 2001;323:471).
Physicians …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.